Enzymatic Deoxyribonucleic Acid (DNA) Synthesis Technology Market Report 2026

The enzymatic deoxyribonucleic acid (dna) synthesis technology market size has grown exponentially in recent years. It will grow from $3.05 billion in 2025 to $3.77 billion in 2026 at a compound annual growth rate (CAGR) of 23.3%. The growth in the historic period can be attributed to increasing use of synthetic biology in research, limitations of chemical dna synthesis methods, growth in genomics and gene editing research, expansion of biotech research funding, availability of enzyme engineering technologies.

The enzymatic deoxyribonucleic acid (dna) synthesis technology market size is expected to see exponential growth in the next few years. It will grow to $8.77 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing demand for scalable dna manufacturing, rising adoption of dna-based data storage concepts, expansion of biopharmaceutical development pipelines, growing investments in sustainable biotech processes, increasing use of automated and microfluidic synthesis systems. Major trends in the forecast period include increasing adoption of enzymatic dna synthesis platforms, growing demand for long and high-fidelity dna constructs, expansion of benchtop and cloud-based synthesis models, rising focus on environmentally sustainable dna manufacturing, enhanced integration with synthetic biology workflows.

The rising adoption of genomics and personalized medicine is anticipated to drive the growth of the enzymatic DNA synthesis technology market in the coming years. Genomics and personalized medicine refer to the use of genetic information and precision healthcare approaches to customize diagnostics, treatments, and preventive strategies for individual genetic profiles. Adoption of genomics and personalized medicine is increasing due to continuous advancements in sequencing technologies that reduce costs and shorten analysis times, improving clinical outcomes and optimizing care efficiency. Enzymatic DNA synthesis technology supports genomics and personalized medicine by enabling scalable, high-precision DNA production essential for creating custom genetic sequences and developing targeted therapies. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six approvals in 2022. Therefore, the rising adoption of genomics and personalized medicine is driving the growth of the enzymatic DNA synthesis technology market.

Companies operating in the enzymatic deoxyribonucleic acid (DNA) synthesis technology market are focusing on developing advanced solutions, such as algorithm-driven enzymatic DNA synthesis platforms, to enable the production of longer, more complex, and highly accurate synthetic DNA sequences. Algorithm-driven enzymatic DNA synthesis platforms leverage advanced computational models to guide enzyme-based, stepwise DNA synthesis in vitro. These systems enhance sequence fidelity, scalability, and output by continuously adapting synthesis conditions using real-time error forecasting and correction mechanisms. For example, in May 2025, Ribbon Bio, an Austria-based synthetic biology company, introduced its MiroSynth DNA molecules designed to unlock a new generation of complex and long synthetic DNA constructs. This algorithm-driven technology enables the assembly of DNA sequences that are significantly longer and more precise than those achievable with conventional methods, supporting advanced applications in gene therapy, synthetic biology, and industrial biotechnology. The solution uses proprietary enzymatic processes to lower error rates, improve scalability, and maintain high sequence accuracy, making it well-suited for demanding downstream biological applications. It is engineered to support the growing demand for complex DNA architectures while offering improved reliability, sustainability, and design flexibility compared with traditional DNA synthesis technologies.

In January 2026, Integrated DNA Technologies, a US-based biotechnology company, partnered with Ansa Biotechnologies to overcome the limitations of traditional chemical DNA synthesis. The collaboration aims to combine Ansa Biotechnologies’ proprietary enzymatic DNA synthesis platform with Integrated DNA Technologies’ global manufacturing and commercialization capabilities to accelerate the development and accessibility of next-generation synthetic DNA for research, diagnostics, and therapeutic applications. Ansa Biotechnologies is a US-based biotechnology company specializing in enzymatic deoxyribonucleic acid (DNA) synthesis technologies.

Major companies operating in the enzymatic deoxyribonucleic acid (dna) synthesis technology market are Thermo Fisher Scientific Inc, Almac Group Limited, Twist Bioscience Corporation, DNA Script SAS, Synbio Technologies, Telesis Bio Inc., Touchlight Genetics Limited, Yeasen Biotechnology, CD Genomics, Bioneer Corporation, Ansa Biotechnologies Inc., Elegen Corporation, Molecular Assemblies Inc., Moligo Technologies AB, Evonetix Ltd, Camena Bioscience Limited, Baseclick GmbH, Kern Systems, Ribbon Bio, and Helixworks.

Tariffs are impacting the enzymatic DNA synthesis technology market by increasing costs of imported enzymes, reagents, microfluidic components, synthesis cartridges, and precision laboratory instruments. Research institutions and biotechnology companies in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces higher costs in equipment sourcing. These tariffs are raising operational expenses and slowing laboratory expansion. However, they are also encouraging localized reagent production, regional instrument manufacturing, and development of cost-efficient synthesis workflows that improve long-term supply resilience.

The enzymatic deoxyribonucleic acid (dna) synthesis technology market research report is one of a series of new reports that provides enzymatic deoxyribonucleic acid (dna) synthesis technology market statistics, including enzymatic deoxyribonucleic acid (dna) synthesis technology industry global market size, regional shares, competitors with a enzymatic deoxyribonucleic acid (dna) synthesis technology market share, detailed enzymatic deoxyribonucleic acid (dna) synthesis technology market segments, market trends and opportunities, and any further data you may need to thrive in the enzymatic deoxyribonucleic acid (dna) synthesis technology industry. This enzymatic deoxyribonucleic acid (dna) synthesis technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enzymatic deoxyribonucleic acid (DNA) synthesis technology is an advanced biotechnological method that employs natural or engineered enzymes, instead of traditional chemical techniques, to assemble DNA strands nucleotide by nucleotide with high precision, accuracy, and efficiency under gentle reaction conditions. This cutting-edge approach allows for faster, more scalable, and environmentally sustainable production of long, intricate, and high-fidelity DNA sequences, enabling diverse applications in synthetic biology, genetic engineering, molecular diagnostics, therapeutic development, and biological data storage.

The major types of enzymatic deoxyribonucleic acid (DNA) synthesis technology include polymerase-mediated synthesis, terminal deoxynucleotidyl transferase, template-free ligase-based synthesis, hybrid chemical-enzymatic workflows, and xeno nucleic acid synthesis platforms. Polymerase-mediated synthesis refers to enzyme-driven methods that assemble DNA sequences with high fidelity for research and industrial applications. These technologies are applied across fragments such as short oligos, gene fragments, and long constructs. The delivery models include benchtop instruments, outsourced services, and cloud-based as a service. The applications include synthetic biology, genomics and gene editing, biopharmaceutical development, diagnostics and research tools, and biotechnology R&D, and the end users are academic and government research institutes, pharmaceutical and biotechnology companies, diagnostic companies, agricultural biotech companies, and industrial biotech and chemical companies.

The enzymatic deoxyribonucleic acid (DNA) synthesis technology market includes sales of benchtop enzymatic synthesizer systems, enzymatic synthesis reagents, enzymatic synthesis enzymes, nucleotide substrates, oligonucleotide products, clonal fragments, long-fragment synthetic kits, synthesis starter kits, reaction buffers for enzymatic synthesis, microfluidic synthesis consumables, synthesis cartridges, and quality control kits for products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.